Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 4, 2011, Pages 356-361

  Pederson, Aaron W ^a   Salama, Joseph K ^b   Witt, Mary Ellen ^a   Stenson, Kerstin M ^a   Blair, Elizabeth A ^a   Vokes, Everett E ^a   Haraf, Daniel J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemoradiotherapy; IMRT; intensity modulated radiotherapy; oral cavity cancer; organ preservation

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ESOPHAGUS STRICTURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOCAL METASTASIS; MALE; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REGIONAL METASTASIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; XEROSTOMIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; MOUTH; MOUTH NEOPLASMS; ORGAN PRESERVATION; QUALITY OF LIFE; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79961173684     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e8420b     Document Type: Article

References (39)

1. Eisbruch A. Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nat Clin Pract Oncol. 2005;2:34-39. (Pubitemid 40823179)
2. Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys. 2009;73:1096-1103.
3. Yao M, Chang K, Funk GF, et al. The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy-the university of iowa experience. Int J Radiat Oncol Biol Phys. 2007;67:1332-1341. (Pubitemid 46467167)
4. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26:3-11. (Pubitemid 23137882)
5. Studer G, Zwahlen RA, Graetz KW, et al. IMRT in oral cavity cancer. Radiat Oncol. 2007;2:16.
6. Kao J, Lavaf A, Teng MS, et al. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: An analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys. 2008;71:362-370.
7. Rusthoven K, Ballonoff A, Raben D, et al. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008;112:345-351.
8. de Bree R, Rinaldo A, Genden EM, et al. Modern reconstruction techniques for oral and pharyngeal defects after tumor resection. Eur Arch Otorhinolaryngol. 2008;265:1-9. (Pubitemid 350160365)
9. Bourhis J. Update of MACH-NC (Meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol. 2004;24:489s.
10. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28.
11. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007;25:4118-4126. (Pubitemid 47492956)
12. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4:156-171. (Pubitemid 46358853)
13. Cohen EE, Haraf DJ, List MA, et al. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006;24:3438-3444. (Pubitemid 46638901)
14. Salama JK, Stenson KM, Kistner EO, et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: A multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008;19:1787-1794.
15. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000;18:1652-1661. (Pubitemid 30220543)
16. Haraf DJ, Stenson K, List M, et al. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997;24(1 suppl 2):S2-68 -S2-71.
17. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26:1732-1741.
18. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003;9:5936-5943. (Pubitemid 38018079)
19. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: The feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000;126:950-956. (Pubitemid 30658293)
20. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination. J Clin Oncol. 1999;17:1020-1028. (Pubitemid 29109336)
21. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570-579. (Pubitemid 23071057)
22. List MA, D'Antonio LL, Cella DF, et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. Cancer. 1996; 77:2294-2301. (Pubitemid 26162422)
23. List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer. 1990;66:564-569. (Pubitemid 20233457)
24. Browman GP, Levine MN, Hodson DI, et al. The head and neck radiotherapy questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol. 1993;11:863-872. (Pubitemid 23146080)
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:547-581.
26. Lee NY, O'Meara W, Chan K, et al. Concurrent chemotherapy and intensitymodulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2007;69:459-468. (Pubitemid 47380087)
27. Studer G, Furrer K, Davis BJ, et al. Postoperative IMRT in head and neck cancer. Radiat Oncol. 2006;1:40.
28. Chao KS, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55:312-321. (Pubitemid 36069088)
29. Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;46:1117-1126. (Pubitemid 30139420)
30. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
31. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-andneck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571-578.
32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354: 567-578. (Pubitemid 43209104)
33. Zelefsky MJ, Harrison LB, Fass DE, et al. Postoperative radiotherapy for oral cavity cancers: Impact of anatomic subsite on treatment outcome. Head Neck. 1990;12:470-475.
34. Stenson KM, Kunnavakkam R, Cohen EE, et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 120:93-99.
35. Cohen EE, Baru J, Huo D, et al. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009;31:1013-1021.
36. Balogh JM, Sutherland SE. Osteoradionecrosis of the mandible: A review. J Otolaryngol. 1989;18:245-250. (Pubitemid 19199945)
37. Studer G, Studer SP, Zwahlen RA, et al. Osteoradionecrosis of the mandible: Minimized risk profile following intensity-modulated radiation therapy (IMRT). Strahlenther Onkol. 2006;182:283-288.
38. Nguyen NP, Chi A, Nguyen LM, et al. Human papillomavirus-associated oropharyngeal cancer: A new clinical entity. QJM. 2010;103:229-236.
39. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.